# DESCRIPTION

## BACKGROUND

- introduce HCN channels
- motivate MDD treatment
- describe HCN channel structure
- summarize TRIP8b-HCN interaction
- discuss HCN channel regulation
- introduce virtual high-throughput screen

## SUMMARY

- disclose compounds as TRIP8b-HCN inhibitors
- define formula I
- describe X substituents
- describe Y substituents
- describe Z substituents
- describe R² substituents
- describe biological activities
- disclose pharmaceutical compositions
- disclose methods for treating MDD

## DETAILED DESCRIPTION

- define terms used throughout the application
- specify meaning of "a", "an", and "the"
- define "about", "approximately", "substantially", and "significantly"
- explain meaning of "include" and "comprising"
- define "subject" and "subject in need of treatment"
- specify meaning of "effective amount"
- define "modulate"
- introduce chemical entities and uses
- explain use of asterisk and plus sign in chemical notation
- define "alkyl"
- define "alkylene"
- define "haloalkyl"
- define "heteroalkyl"
- define "alkenyl"
- define "alkynyl"
- define "cycloalkyl"
- define "cycloheteroalkyl"
- define "cycloalkylene"
- define "partially unsaturated carbocyclyl"
- define "aryl"
- define "heterocyclyl"
- define "amine" and "amino"
- define "alkoxy" and "alkoxyl"
- define "ether"
- define "carbonyl"
- define "oxo"
- define "carboxamido"
- define "carboxy"
- define "amide" and "amido"
- discuss stereoisomers
- introduce inhibitors of TRIP8b and uses
- describe compounds of formula I
- specify embodiments of X in formula I
- specify embodiments of R² in formula I
- define compounds of formula I
- specify m values
- specify R1 values
- specify W values
- specify Y values
- specify Z values
- specify R2 values
- specify R3 values
- specify R4 values
- describe pharmaceutical compositions
- describe methods for treating diseases
- describe biological activities
- describe TRIP8b-HCN1 interaction
- describe concentration ranges
- describe toxicity
- describe pharmaceutical composition formulation
- describe administration methods
- describe treatment methods
- describe dose ranges
- describe minimal and maximal dose levels
- describe pharmaceutical composition dosage forms
- list pharmaceutical composition components
- describe filling agents
- describe binding agents
- describe lubricants
- describe sweeteners
- describe flavoring agents
- describe preservatives
- describe diluents
- describe disintegrants
- describe effervescent agents
- describe pharmaceutical composition formulation
- describe oral administration
- describe pharmaceutical composition preparation
- describe administration routes
- describe oral administration forms
- describe transdermal administration
- describe topical administration
- describe ophthalmic administration
- describe nasal administration
- describe parenteral administration
- list compounds with TRIP8b-HCN1c40 Alphascreen IC50 activity

### Examples

- introduce in silico screening
- filter out promiscuous molecules
- prepare protein for docking simulations
- analyze atomic structure of TRIP8b
- correct protein structure
- generate grid cube for docking
- perform virtual screening
- analyze docking results
- select compounds for biochemical testing
- perform biochemical screening
- determine IC50 value
- validate binding mode using STD-NMR
- perform STD-NMR experiment
- analyze STD-NMR results
- determine solubility of NUCC-0200590
- prepare salt forms of NUCC-0200590
- compare solubility of salt forms
- determine microsomal stability
- describe synthetic route for compounds
- provide exemplary synthetic route for NUCC-0200590
- alkylate 5-bromosalicylaldehyde
- perform reductive amination
- hydrolyze ester
- perform amide coupling
- perform Suzuki coupling
- describe synthesis of 2-(4-bromo-2-((4-methylpiperazin-1-yl)methyl)phenoxy
- describe synthesis of 2-(4-bromo-2-((4-methylpiperazin-1-yl)methyl)phenoxy
- describe synthesis of N-(4-chlorobenzyl)-2-((4′-fluoro-3-((4-methylpiperaz
- describe synthesis of N-(4-chlorobenzyl)-2-((4′-fluoro-3-((4-methylpiperaz
- describe synthesis of N-(4-chlorobenzyl)-2-((4′-fluoro-3-((4-methylpiperaz
- describe synthesis of N-(4-chlorobenzyl)-2-((4′-fluoro-3-((4-methylpiperaz
- describe STD-NMR experiment
- describe cellular assays
- describe cell viability assays
- describe flow cytometry
- describe HEK electrophysiology
- describe slice electrophysiology
- describe immunohistochemistry
- describe NanoBiT live cell protein-protein interaction assay
- describe AlphaScreen assay
- describe TRIP8b-HCN interaction
- describe HCN channel trafficking
- describe TRIP8b isoforms
- describe HCN isoforms
- describe cell-based assays
- describe FA version of compound
- describe TRIP8b(1a-4) isoform
- describe HCN1 and HCN2 subunits
- describe electrophysiological properties
- describe cell viability
- describe surface expression evaluation
- describe HEK cell transfection
- describe statistical analyses

